Brain Cancer @ Leeds

Dr Lynette Steele – Senior Research Technician

Contact Information

Dr Lynette Steele
Senior Research Technician
Translational Neuro-oncology
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St.James’s University Hospital
Beckett Street
Leeds
LS9 7TF

tel: +44 (0) 113 343 8513
email: L.P.Steele@leeds.ac.uk

Background

I am a Senior Research Technician currently involved in investigating potential new therapeutic agents for the treatment of adult and paediatric glioblastoma. My background is in cancer cell biology with a particular interest in cell death and apoptotic pathways. My role involves administrative duties for Lab 6 WTBB including overseeing budgets and various health and safety duties. I am also PD for the Neuro-oncology arm of the Multidisciplinary Research Tissue Bank headed by Prof Roz Banks.

Resume

Publications

Levesley, J., L. Steele, et al. (2013). “ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death.” PLoS One 8(5): e64051.
Donnelly, O. G., F. Errington-Mais, et al. (2013). “Measles virus causes immunogenic cell death in human melanoma.” Gene Ther 20(1): 7-15.

Steele, L., F. Errington, et al. (2011). “Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming.” Mol Cancer 10: 20.

Harvey, T. J., D. Burdon, et al. (2010). “Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.” Gene Ther 17(8): 1000-1010.

Prestwich, R. J., F. Errington, et al. (2009). “Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.” J Immunol 183(7): 4312-4321.

Prestwich, R. J., E. J. Ilett, et al. (2009). “Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.” Clin Cancer Res 15(13): 4374-4381.

Hill, K. S., F. Errington, et al. (2008). “OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions.” J Immunol 181(5): 3108-3115.

Errington, F., L. Steele, et al. (2008). “Reovirus activates human dendritic cells to promote innate antitumor immunity.” J Immunol 180(9): 6018-6026.

Errington, F., C. L. White, et al. (2008). “Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.” Gene Ther 15(18): 1257-1270.

Georgopoulos, N. T., L. P. Steele, et al. (2006). “A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.” Cell Death Differ 13(10): 1789-1801.

Steele, L. P., N. T. Georgopoulos, et al. (2006). “Differential susceptibility to TRAIL of normal versus malignant human urothelial cells.” Cell Death Differ 13(9): 1564-1576.

© Copyright Leeds 2017